# Richard S. Kollender > Richard S. Kollender is a Series D investor at Quaker BioVentures backing Health Care. See 1 investments, check sizes, portfolio and contact details. Updated… - Type: Angel Investor - Fund: [Quaker BioVentures](https://shizune.co/investors/profile/quaker-bioventures) - Total investments: 1 - Last investment: Apr 2008 - Lead investor: 100% - Last updated: Aug 2026 Richard S. Kollender is a Series D investor at Quaker BioVentures focused on Health Care and Biotechnology. Joined Quaker BioVentures in 2003 and promoted to Partner in 2005 Previously: Held positions in sales, marketing and worldwide business development at GlaxoSmithKline. Also served as investment manager at S.R. One where he evaluated potential investment opportunities, performed due diligence, structured and negotiated investments and worked withmanagement teams to execute their strategies following investment. Began his career as a CPA with KPMG Peat Marwick with an emphasis on the healthcare and emerging businesses sectors. Board Responsibilities: Nupathe, Precision Therapeutics, TargetRx, Transave, and Transport Pharmaceuticals Board Observer Responsibilities: Amicus Therapeutics and Celator Pharmaceuticals Prior Board Participation: Medmark Other: Public Policy Committee Member for Pennsylvania Bio and Advisory Committee Member for Mid-Atlantic Venture Association. Member of both the American and Pennsylvania Institutes of Certified Public Accountants. Education: B.A. from Franklin and Marshall College, M.B.A. and Health Administration & Policy degrees with Honors from the University of Chicago ## Contacts 5 contacts available for Richard S. Kollender: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/richard-s-kollender?utm_source=investor_profile ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Health Care | 1 | 100% | | Biotechnology | 1 | 100% | | Medical Device | 1 | 100% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Transave | Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients;and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated. | $35M | Series D | Apr 02, 2008 | | 1 of 1 investments shown. ## Co-investors - [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund, 1 deal together - [Easton Capital](https://shizune.co/investors/profile/easton-capital) — VC Fund, 1 deal together - [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 1 deal together - [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 1 deal together - [Prospect Venture Partners](https://shizune.co/investors/profile/prospect-venture-partners) — VC Fund, 1 deal together - [TVM Capital](https://shizune.co/investors/profile/tvm-capital) — VC Fund, 1 deal together ## About Quaker BioVentures VC Fund · Philadelphia, United States Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. Quaker BioVentures invests in companies at all stages of development,from early stage start-ups to public companies. Founded in 2003, the firm is currently investing Quaker BioVentures II, a $420 million fund formed in 2007. Quaker BioVentures manages over $700 million in committed capital. 5 contacts available at Quaker BioVentures. | Name | Title | Profile | | --- | --- | --- | | Brenda D. Gavin | Partner | https://shizune.co/investors/profile/brenda-d-gavin | | Richard S. Kollender | Partner | — | | Adele C. Oliva | Partner | — | | Geeta Vemuri | Partner | https://shizune.co/investors/profile/geeta-vemuri | | Ira Lubert | Founding Partner | — | ## Similar investors ### Similar stage - [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund - [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund - [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund ## FAQ ### What does Richard S. Kollender invest in? Richard S. Kollender invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series D stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### How do I contact Richard S. Kollender? For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox. ### When did Richard S. Kollender last invest? The most recent investment recorded for Richard S. Kollender closed in Apr 2008. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co